Use of a gene expression signature to identify trimetazidine for repurposing to treat bipolar depression

• Published in: Bipolar disorders Vol. 25; no. 8; pp. 661 - 670
• Main Authors: Bortolasci, Chiara C., Kidnapillai, Srisaiyini, Spolding, Briana, Truong, Trang T. T., Connor, Timothy, Swinton, Courtney, Panizzutti, Bruna, Liu, Zoe S. J., Sanigorski, Andrew, Dean, Olivia M., Crowley, Tamsyn, Richardson, Mark, Bozaoglu, Kiymet, Vlahos, Katerina, Cowdery, Stephanie, Watmuff, Brad, Steyn, Stephan F., Wolmarans, De Wet, Engelbrecht, Barend J., Perry, Christina, Drummond, Katherine, Pang, Terence, Jamain, Stéphane, Gray, Laura, McGee, Sean L., Harvey, Brian H., Kim, Jee Hyun, Leboyer, Marion, Berk, Michael, Walder, Ken
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.12.2023; Wiley; John Wiley and Sons Inc
• Subjects: Animal models; Animals; Astrocytes; bipolar depression; Bipolar disorder; Bipolar Disorder - drug therapy; Bipolar Disorder - genetics; Cell differentiation; Disease Models, Animal; Drug Repositioning; drug repurposing; Electron transport; Gene expression; gene expression signature; Hedonic response; Humans; Leukocytes, Mononuclear; Life Sciences; MAP kinase; Mental depression; Neurotrophin 2; Original; Peripheral blood mononuclear cells; Pluripotency; Rats; Signal transduction; Social interactions; Stem cells; Transcriptome; Transcriptomics; Trimetazidine; Trimetazidine - pharmacology; Trimetazidine - therapeutic use; bipolar depression; drug repurposing; gene expression signature; trimetazidine

Objectives The aim of this study was to repurpose a drug for the treatment of bipolar depression. Methods A gene expression signature representing the overall transcriptomic effects of a cocktail of drugs widely prescribed to treat bipolar disorder was generated using human neuronal‐like (NT2‐N) cel...